University of Texas's MD Anderson Cancer: Preoperative Combination Chemotherapy Improved Survival in Patients With Pancreatic Cancer
July 15, 2022
July 15, 2022
HOUSTON, Texas, July 15 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on July 14, 2022:
* * *
NCI Alliance trial establishes FOLFIRINOX as preferred treatment regimen
* * *
In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased survival relative to historical data and compared favorably to FOLFIRINOX . . .
* * *
NCI Alliance trial establishes FOLFIRINOX as preferred treatment regimen
* * *
In a study of patients with borderline resectable pancreatic cancer, combination chemotherapy with modified FOLFIRINOX before surgery increased survival relative to historical data and compared favorably to FOLFIRINOX . . .